Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis

Francisco Gomez-Veiga,Russell Z. Szmulewitz,Jeffrey Holzbeierlein,Arun A. Azad,Taro Iguchi,Arnauld Villers,Antonio Alcaraz,Boris Alekseev,Neal D. Shore,Brad Rosbrook,Fabian Zohren,Jie Ma,Gabriel P. Haas,Arnulf Stenzl,Andrew J. Armstrong

European Urology Oncology（2023）

引用 0|浏览1

暂无评分

摘要

Treatment intensification of androgen deprivation therapy with enzalutamide demonstrated clinical benefits in patients with metastatic hormone-sensitive prostate cancer aged <75 or ≥75 yr and was generally well tolerated, irrespective of age, with no substantial impact on quality of life.

查看译文

关键词

Age,Enzalutamide,Metastatic hormone-sensitive prostate cancer,Overall survival,Progression-free survival,Treatment efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要